Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories

Forms and Documents

Document	Type	Status	Availability
1117-0034 Updated Supporting Statement (A and B).docx	Supporting Statement B	Uploaded 2018-12-18	Available
Medical Examiner-Toxicology Data Collection Items.docx	Supplementary Document	Uploaded 2018-09-06	Repair queued
Implementing an Medical Examiner-Coroner Office and Toxicology Laboratory Data Collection Overview.docx	Supplementary Document	Uploaded 2018-09-06	Repair queued
OMB 1117-0034 Final Supporting Statement 9-6-18.docx	Supporting Statement A	Uploaded 2018-09-06	Repair queued
NFLIS Reporting.docx	Supplementary Document	Uploaded 2010-01-15	Available
21 USC 873.rtf	Supplementary Document	Uploaded 2009-12-10	Available

IC Document Collections

IC ID	Collection	Type	Status	Form
12339	Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories (monthly)	Other-Survey	Modified

ICR Details

OMB Control No: 1117-0034	ICR Reference No: 201806-1117-001
Status: Historical Inactive	Previous ICR Reference No: 201511-1117-001
Agency/Subagency: DOJ/DEA	Agency Tracking No:
Title: Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories
Type of Information Collection: Revision of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Improperly submitted and continue	Conclusion Date: 12/17/2018
	Date Received in OIRA: 09/06/2018
Terms of Clearance:

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	05/31/2019	36 Months From Approved	12/31/2019
Responses	1,632	0	1,632
Time Burden (Hours)	218	0	218
Cost Burden (Dollars)	9,047	0	9,047

---

Abstract: This collection provides the Drug Enforcement Administration (DEA) with a national database on analyzed drug evidence from non-federal laboratories. Information from this database is combined with other existing databases to develop more accurate, up-to-date information on abused drugs. This database represents a voluntary, cooperative effort on the part of participating laboratories to provide a centralized source of analyzed drug data. Existing federal drug abuse databases do not provide the type, scope or quality of information necessary to effectively estimate the actual or relative abuse potential of drugs as required under the Controlled Substances Act (21 U.S.C. 811(b)) and international treaties in a timely and efficient manner.

---

Authorizing Statute(s): US Code: 21 USC 873 Name of Law: Controlled Substances Act
   US Code: 21 USC 811 (b) Name of Law: Controlled Substances Act and international treaties
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	83 FR 27022	06/11/2018
30-day Notice:	Federal Register Citation:	Citation Date:
	83 FR 38324	08/06/2018
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories (monthly)

---

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to: Miscellaneous Actions

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: The burden is changed to reflect the three additional activities under the current collection. The data collected from the NFLIS-Drug survey is needed to support ongoing and accurate statistical analysis and reporting for the existing NFLIS-Drug ongoing data collection. The two new future continuous data collections—i.e., NFLIS-MEC and NFLIS-Tox—will provide the Diversion Control Division with two more important sources of information to identify new and emerging substances of abuse for scheduling purposes, monitoring the trends of known drugs of abuse, and surveil the diversion of licit substances, all of which are needed to carry out the Diversion Control Division’s core mission.

---

Annual Cost to Federal Government: $1,920,897

Does this IC contain surveys, censuses, or employ statistical methods? No

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     Yes

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/06/2018

---